TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04167644

Intervention type: DIAGNOSTIC_TEST
Intervention: Modified Rankin Scale (mRS)
Description: Modified Rankin Scale (mRS) is a profoundly valid and reliable measure of disability and is broadly utilized for assessing stroke outcomes and degree of disability. We characterized a favorable outcome as mRS ranging from zero up to two, while unfavorable outcome ranging for 3 up to six

Intervention type: DIAGNOSTIC_TEST
Intervention: Modified Rankin Scale (mRS)
Description: Modified Rankin Scale (mRS) is a profoundly valid and reliable measure of disability and is broadly utilized for assessing stroke outcomes and degree of disability. We characterized a favorable outcome as mRS ranging from zero up to two, while unfavorable outcome ranging for 3 up to six
Study: NCT00706823

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: i-gel airway (Intersurgical Ltd., Wokingham, England)
Description: supra-glottic airway device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngeal Mask Airway-Unique
Description: supra-glottic airway device
Study: NCT04112056

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Drink the study formula (NAN Comfort producted by Nestle Deutschland AG)
Description: It is same as that stated in arm description.
Study: NCT03719885

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TrueTear Intranasal Tear Neurostimulator
Description: This study will evaluate the immediate tear production resulting from use of intranasal tear neurostimulation in patients with Sjogren's disease
Study: NCT00937326

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SRT2104
Description: SRT2104 will be supplied as hard gelatin capsules, with each containing 250 mg.
Study: NCT03346785

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food Photography
Description: Participants will engage in food photography on their smart phones while eating

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-Food Photography
Description: Participants will engage in non-food photography on their smart phones while eating

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Phone Use
Description: Participants will not use their smart phones while eating
Study: NCT00798499

Intervention type: OTHER
Intervention: Laboratory variables
Description: 1 visit
Study: NCT05329974

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computer guided buccal cortical plate separation
Description: Computer guided buccal cortical plate separation for removal of calcified benign odontogenic tumors
Study: NCT02656784

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Therapy
Description: Trial-Based Cognitive Therapy (TBCT) is a three-level, three-phase, case formulation approach. TBCT's foundation is in cognitive therapy (CT); however, it has a unique approach to conceptualization and techniques that make it a distinct intervention in modifying patients' core beliefs, especially those about the self. All the individuals will be submitted to MRI.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Therapy
Description: The Behavioral therapy employs the technique of Exposure and Response Prevention ( ERP ).The technique involves directly exposing patients to recall stimulation of obsessive thoughts and prevent them from performing the compulsive rituals. All the individuals will be submitted to MRI.
Study: NCT00612040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Formulation 1: Treat-to-target dose titration scheme, injection s.c. (under the skin), once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Formulation 2: Treat-to-target dose titration scheme, injection s.c. (under the skin), once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine
Description: Treat-to-target dose titration scheme, injection s.c., once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: Treat-to-target dose titration scheme, injection s.c. (under the skin), 3 times daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: Treat-to-target dose titration scheme, injection s.c. (under the skin), 3 times daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: Treat-to-target dose titration scheme, injection s.c. (under the skin), 3 times daily
Study: NCT03169556

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Video-laryngoscope guided lightwand
Description: After anesthetic induction,the difficult airway is simulated by wearing a semi-hard neck collar. For intubation, video-laryngoscope is inserted into the oral cavity ntil the epiglottis tip was visible without lifting the epiglottic vallecula. Then, the endotracheal tube with lightwand is inserted toward the midline under the epiglottis and the intubation is performed looking the transilluminated light of lightwand.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lightwand alone
Description: After anesthetic induction,the difficult airway is simulated by wearing a semi-hard neck collar. Then, the endotracheal tube with lightwand is inserted and the intubation is performed with conventional method (blind technique by confirming transillumination).
Study: NCT01874613

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FRC implant reconstruction
Description: A cranioplasty with the FRC implant is performed.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FRC implant reconstruction
Description: The orbital floor fracture is reconstructed with the FRC implant.
Study: NCT02131194

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lenstatin
Description: Dietary Supplement Lenstatin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo sugar pill manufactured to mimic Lenstatin
Study: NCT02380781

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information in the form of a video
Description: see intervention description
Study: NCT01001377

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Administered by intravenous infusion
Study: NCT04442867

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Case management
Description: Based on the clients' problems, individualized and specific health education such as recognition of the early signs and symptoms of an exacerbation or deterioration of disease condition, the frequency, dosage, duration of each health-promoting activity that was of therapeutic value, and the techniques required to perform these activities will be provided by the Nurse Case Manager.

Intervention type: OTHER
Group type: OTHER
Intervention: Social call
Description: Provide social call to participants, such as ask the participants what TV program do you like most, and how are you recently.
Study: NCT01342302

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Psychosocial Intervention for Couples
Description: Intervention delivered on line
Study: NCT04535700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone 30 mg
Description: Patients receive 30 mg/day of pioglitazone for the entire period they remain in hospital

Intervention type: OTHER
Group type: OTHER
Intervention: standard of care
Description: Patients receive the standard of care, according to the hospital protocol for patients with type 2 diabetes mellitus hospitalized.
Study: NCT01119794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab and Bortezomib
Description: Ofatumumab 1000 mg IV Cycle 1 on day 1, 8, 15 and 22 Bortezomib 1.6 mg/m2 IV Ofatumumab 1000 mg IV on day 1 maintenance phase Patients will remain until progression
Study: NCT04320654

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: The aim of this intervention is to increase patients average daily step count. The walking program is a behavior change intervention in which the pedometer will be used as a tool to help the patients monitor their activity levels.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: The aim of this intervention is to increase patients average daily step count. The walking program is a behavior change intervention in which the pedometer will be used as a tool to help the patients monitor their activity levels.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: The aim of this intervention is to increase patients average daily step count. The walking program is a behavior change intervention in which the pedometer will be used as a tool to help the patients monitor their activity levels.
Study: NCT01532310

Intervention type: DRUG
Intervention: belimumab
Description: Belimumab is a recombinant, human, IgG1λ monoclonal antibody for the treatment of systemic lupus erythematosus
Study: NCT03385902

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: optimal start time
Description: patients will start hemodialysis when their DIFE reach 35, and can not wait if the DIFE decline to 30.
Study: NCT04164316

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Kinesio Tape
Description: Kinesio TexTM Tape which is the original elastic therapeutic adhesive tape which is a latex-free, hypoallergenic, waterproof, porous.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Kinesio Tape
Description: Kinesio TexTM Tape which is the original elastic therapeutic adhesive tape which is a latex-free, hypoallergenic, waterproof, porous.
Study: NCT03385902

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: late start time
Description: patients will start hemodialysis when their DIFE less than 30
Study: NCT02134795

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TNM (trade name), a form of brainstem Stimulation
Description: The device is worn like a music headset and the patient lies on a wedge pillow while the device is active. Each session lasts under 20 minutes. The stimulation is non-invasive and non-electrical. The form of stimulation acts on the brainstem.
Study: NCT01696994

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Screening Questionnaire Administration
Description: Undergo questionnaire assessments

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound Imaging
Description: Undergo TVU
Study: NCT03406871

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regorafenib
Description: One course will last 28 days. Oral administration for 21 consecutive days, with a 1-week washout period. As for the expansion cohort, implemented using the RD estimated in the dose-escalation cohort.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regorafenib
Description: One course will last 28 days. Oral administration for 21 consecutive days, with a 1-week washout period. As for the expansion cohort, implemented using the RD estimated in the dose-escalation cohort.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regorafenib
Description: One course will last 28 days. Oral administration for 21 consecutive days, with a 1-week washout period. As for the expansion cohort, implemented using the RD estimated in the dose-escalation cohort.
Study: NCT04320654

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: The aim of this intervention is to increase patients average daily step count. The walking program is a behavior change intervention in which the pedometer will be used as a tool to help the patients monitor their activity levels.
Study: NCT00732576

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: menaquinone-7
Description: capsule consisting of 10, 20 or 45 µg menaquinone-7 per day during 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: menaquinone-7
Description: capsule consisting of 10, 20 or 45 µg menaquinone-7 per day during 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: menaquinone-7
Description: capsule consisting of 10, 20 or 45 µg menaquinone-7 per day during 8 weeks
Study: NCT01651377

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pramipexole
Description: Participants will receive pramipexole ER 0.375, .075, 1.5, 2.25, and 3mg/d in an ascending-dose pattern.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo pills. The placebo group is included to maintain the blind, rather than as a comparison group.
Study: NCT04525378

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mesenchymal stromal cell-based therapy
Description: Intravenous administration of MSCs, performed as single dose (high dose group) or repeated after 48 h (low doses; intermediate dose)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mesenchymal stromal cell-based therapy
Description: Intravenous administration of MSCs, performed as single dose (high dose group) or repeated after 48 h (low doses; intermediate dose)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mesenchymal stromal cell-based therapy
Description: Intravenous administration of MSCs, performed as single dose (high dose group) or repeated after 48 h (low doses; intermediate dose)
Study: NCT03853408

Intervention type: PROCEDURE
Intervention: Cholecystectomy
Description: Cholecystectomy (removal of the gallbladder) for acute cholecystitis

Intervention type: PROCEDURE
Intervention: Cholecystectomy
Description: Cholecystectomy (removal of the gallbladder) for acute cholecystitis
Study: NCT01461603

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vamin (Fresenius Kabi)
Description: Vamin 18gN 1ml/min infusion in 6 hours

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 3hydroxybutyrate
Description: Goldbio, FFA-3OHB, dry powder mixed with sterile water at Aarhus University hospital pharmacy.
Study: NCT00937326

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SRT2104
Description: SRT2104 will be supplied as hard gelatin capsules, with each containing 250 mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SRT2104
Description: SRT2104 will be supplied as hard gelatin capsules, with each containing 250 mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo will be supplied as hard gelatin capsules, with each containing an appropriate amount of placebo.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo will be supplied as hard gelatin capsules, with each containing an appropriate amount of placebo.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo will be supplied as hard gelatin capsules, with each containing an appropriate amount of placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be supplied as hard gelatin capsules, with each containing an appropriate amount of placebo.
Study: NCT02589743

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sealant
Description: Application of preventive agent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sealant
Description: Application of preventive agent

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adhesive and Sealant
Description: Application of preventive agent and technique for control moisture

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adhesive and Sealant
Description: Application of preventive agent and technique for control moisture
Study: NCT03785470

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fructose and physical inactivity
Description: Subjects will drink 6 cans of regular sodas daily (divided throughout the day) and will decreased physical activity to less than 5000 steps daily for 10 days.
Study: NCT01529619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivastigmine transdermal patch
Study: NCT00479167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib and Tositumomab I-131
Study: NCT00732576

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: menaquinone-7
Description: capsule consisting of 10, 20 or 45 µg menaquinone-7 per day during 8 weeks
Study: NCT03417505

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scleral lenses treated with Tangible Hydra-PEG
Description: Scleral lenses treated with Tangible Hydra-PEG, a hydrophilic, PEG-based contact lens coating designed to improve lens wettability, deposit resistance, and tear film breakup time.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scleral lenses treated with Tangible Hydra-PEG
Description: Scleral lenses treated with Tangible Hydra-PEG, a hydrophilic, PEG-based contact lens coating designed to improve lens wettability, deposit resistance, and tear film breakup time.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Untreated scleral lenses
Description: Scleral lenses without the Tangible Hydra-PEG treatment will serve as a control.
Study: NCT00732576

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: menaquinone-7
Description: capsule consisting of 10, 20 or 45 µg menaquinone-7 per day during 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: menaquinone-7
Description: capsule consisting of 10, 20 or 45 µg menaquinone-7 per day during 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: fish oil
Description: 9 fish oil capsules equivalent to 3 gram per day of n-3 polyunsaturated fatty acids during 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: fish oil
Description: 9 fish oil capsules equivalent to 3 gram per day of n-3 polyunsaturated fatty acids during 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: fish oil
Description: 9 fish oil capsules equivalent to 3 gram per day of n-3 polyunsaturated fatty acids during 12 weeks
Study: NCT03417505

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Untreated scleral lenses
Description: Scleral lenses without the Tangible Hydra-PEG treatment will serve as a control.
Study: NCT03796195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: .5% Bupivacaine
Description: Ultrasound guided right sided stelate ganglion block using .5% bupivacaine (5mLs)
Study: NCT02455362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine sulfate
Description: Treatment with sustained-release morphine sulfate is given as one double-blind capsule in the morning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine sulfate
Description: Treatment with sustained-release morphine sulfate is given as one double-blind capsule in the morning.
Study: NCT00732576

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: fish oil
Description: 9 fish oil capsules equivalent to 3 gram per day of n-3 polyunsaturated fatty acids during 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: krill oil
Description: 9 krill oil capsules, equivalent to 1,5 gram per day of n-3 polyunsaturated fatty acids (PUFA) during 12 weeks
Study: NCT02455362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine sulfate
Description: Treatment with sustained-release morphine sulfate is given as one double-blind capsule in the morning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine sulfate
Description: Treatment with sustained-release morphine sulfate is given as one double-blind capsule in the morning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine sulfate
Description: Treatment with sustained-release morphine sulfate is given as one double-blind capsule in the morning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine sulfate
Description: Treatment with sustained-release morphine sulfate is given as one double-blind capsule in the morning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine sulfate
Description: Treatment with sustained-release morphine sulfate is given as one double-blind capsule in the morning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine sulfate
Description: Treatment with sustained-release morphine sulfate is given as one double-blind capsule in the morning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine sulfate
Description: Treatment with sustained-release morphine sulfate is given as one double-blind capsule in the morning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine sulfate
Description: Treatment with sustained-release morphine sulfate is given as one double-blind capsule in the morning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine sulfate
Description: Treatment with sustained-release morphine sulfate is given as one double-blind capsule in the morning.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00732576

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: krill oil
Description: 9 krill oil capsules, equivalent to 1,5 gram per day of n-3 polyunsaturated fatty acids (PUFA) during 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: krill oil
Description: 9 krill oil capsules, equivalent to 1,5 gram per day of n-3 polyunsaturated fatty acids (PUFA) during 12 weeks
Study: NCT02663180

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational program
Description: Educational strategies: 2 Lecture about depression 30 minutes supported by group discussion, brochures and display of posters with mental-health slogans on depression in the schools.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video contact
Description: Contact strategies: Investigators will show a video of a young male who had been diagnosed with depression. The video presented information that was moderately disconfirming of prior stereotypes by balancing the individual's difficulties resulting from Depression, with his ability to live a normal life.
Study: NCT00732576

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: krill oil
Description: 9 krill oil capsules, equivalent to 1,5 gram per day of n-3 polyunsaturated fatty acids (PUFA) during 12 weeks
Study: NCT03510780

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periodontal surgery with Enamel Matrix Derivative
Description: Patients will be treated by periodontal surgical flaps with the addition of EMD + bone graft

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periodontal surgery with Platlet Rich fibrin
Description: Patients will be treated by periodontal surgical flaps with the addition of PRF + bone graft
Study: NCT04620135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Netarsudil ophthalmic solution 0.02%
Description: Topical sterile ophthalmic solution Other Name: Rhopressa®

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ripasudil hydrochloride hydrate ophthalmic solution 0.4%
Description: Other Name: Glanatec®